Credit Agricole’s CRISPR Therapeutics CRSP Stock Holding History

Credit Agricole’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$44.2K	Hold	1,300	–	–	﹤0.01%	1167
2024 Q4	$51.2K	Hold	1,300	–	–	﹤0.01%	1181
2024 Q3	$61.1K	Hold	1,300	–	–	﹤0.01%	1139
2024 Q2	$70.2K	Hold	1,300	–	–	﹤0.01%	982
2024 Q1	$73K	Hold	1,300	–	–	﹤0.01%	774
2023 Q4	$81.4K	Hold	1,300	–	–	﹤0.01%	759
2023 Q3	$59K	Hold	1,300	–	–	﹤0.01%	774
2023 Q2	$73K	Hold	1,300	–	–	﹤0.01%	501
2023 Q1	$58.8K	Hold	1,300	–	–	﹤0.01%	491
2022 Q4	$52.8K	Hold	1,300	–	–	﹤0.01%	521
2022 Q3	$85K	Hold	1,300	–	–	﹤0.01%	469
2022 Q2	$79K	Sell	1,300 -100	-7%	-$5.88K	﹤0.01%	476
2022 Q1	$88K	Sell	1,400 -5,200	-79%	-$327K	﹤0.01%	485
2021 Q4	$500K	Buy	6,600 +5,000	+313%	+$437K	0.01%	345
2021 Q3	$179K	Buy	+1,600	New	+$201K	﹤0.01%	395

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Agricole's CRSP Position: Q1 2025 in Review

Credit Agricole held its CRISPR Therapeutics (CRSP) position steady in Q1 2025 at 1,300 shares worth $44.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Credit Agricole first reported a position in CRSP in Q3 2021 and has held it in 15 quarters since. The position peaked at $500K in Q4 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Credit Agricole held 1,300 shares of CRISPR Therapeutics worth $44.2K as of Q1 2025.
Credit Agricole left its CRISPR Therapeutics share count unchanged in Q1 2025.
CRISPR Therapeutics made up ﹤0.01% of Credit Agricole's portfolio in Q1 2025, its #1167 holding.
Credit Agricole first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 15 quarters since.
Credit Agricole's CRISPR Therapeutics position peaked at $500K in Q4 2021.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Credit Agricole's 13F filing for Q1 2025, filed 14 May 2025.